CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.
You may also be interested in...
Drug Pricing Critic Peter Bach Named Chair Of Medicare Advisory Panel
But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.
Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria
“Improvement in health outcomes” standard would interpret “the statute to require both diagnosis and treatment,” Lilly says about CMS’ recent evaluation of beta-amyloid positron emission tomography in dementia and neurodegenerative disease.